Oxford’s COVID-19 Vaccine Makers To Parallel Clinical Studies
Merck KGaA, Halix NV, And Others Combine Expertise
An industry consortium will drive forward new manufacturing processes in parallel with the Oxford group’s COVID-19 vaccine clinical studies; these studies could produce Phase III efficacy results by this autumn.
